Loading organizations...
Ingenix, based in Warsaw, Poland, develops a proprietary multimodal and multiscale generative AI co-pilot designed to simulate clinical trials using digital twins for pharmaceutical and biotech companies. The platform integrates biological and medical data from various sources, including text, bioimaging, and 3D structures, to optimize drug candidate selection and pre-clinical processes, aiming to reduce drug development timelines. The company recently secured €9 million in seed funding led by Inovo.vc, with participation from OTB Ventures and International Finance Corporation (IFC). Founders Piotr Surma and Adam Dancewicz previously built Applica, which was acquired by Snowflake. Ingenix was founded in 2023 by Piotr Surma and Adam Dancewicz. The firm focuses on pharmaceutical R&D, biotech, and clinical trials, targets pre-clinical development teams and pharma companies globally.
Ingenix has raised $10.6M across 1 funding round.
Ingenix has raised $10.6M in total across 1 funding round.
Ingenix has raised $10.6M in total across 1 funding round.
Ingenix's investors include Inovo Venture Partners.
Ingenix has raised $10.6M across 1 funding round. Most recently, it raised $10.6M Seed in April 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 8, 2025 | $10.6M Seed | Inovo Venture Partners |
